Barclays’s Coya Therapeutics COYA Stock Holding History

Barclays’s Portfolio COYA Stock Details COYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$661	Buy	+113	New	+$523	﹤0.01%	4971

Other funds holding COYA

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Barclays's COYA Position: Q2 2026 in Review

Barclays opened a new position in Coya Therapeutics (COYA) in Q2 2026: 113 shares worth $661. The stake represents ﹤0.01% of the portfolio and ranks #4971 among its holdings.

54 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

Barclays held 113 shares of Coya Therapeutics worth $661 as of Q2 2026.
Coya Therapeutics was a new Barclays position in Q2 2026.
Coya Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4971 holding.
54 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.